Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 7729 - 7736 of 12086 results
Carbon Reduction Reshapes a Regional Electricity Market
October 24, 2016| Blog| Viewpoint
Full Seventh Circuit Bench to Decide Whether Title VII Prohibits Sexual Orientation Discrimination
October 24, 2016| Blog| Viewpoint
3 Guidelines to Maximize Value of Data
October 24, 2016| Blog| Viewpoint
Reminder: Pharmaceutical Industry Enforcement Webinar - Wednesday, October 26
October 24, 2016| Blog| Viewpoint
Providers, Pharmacists Call for Earlier FDA Guidance on Biosimilars
October 24, 2016| News
Coming Soon to a Lawbook Near You - New Cosmetic Requirements
October 21, 2016| Blog| Viewpoint
Analyzing Patent Claims Having Conditional Language – the PTAB Provides Clarity
October 21, 2016| Blog| Viewpoint
Attorney General Kamala D. Harris Provides New Online Tool to Report California Online Privacy Protection Act (CalOPPA) Violations
October 20, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|